title: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.
abstract: Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.
authors.affiliation: Neuro-Oncology Unit, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: Michael A
authors.initials: MA
authors.lastname: Vogelbaum
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: David R
authors.initials: DR
authors.lastname: Macdonald
authors.forename: Susan M
authors.initials: SM
authors.lastname: Chang
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy*; D018450:Disease Progression; D005910:Glioma / Q000628:therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design